1. Sarcopenia and myosteatosis at presentation adversely affect survival after esophagectomy for esophageal cancerMatevž Srpčič, Taja Jordan, Karteek Popuri, Mihael Sok, 2020, izvirni znanstveni članek Ključne besede: esophageal cancer, esophagectomy, muscle depletion, myosteatosis, sarcopenia, survival
Objavljeno v DiRROS: 12.07.2024; Ogledov: 433; Prenosov: 146
 Celotno besedilo (569,08 KB) |
2. Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006Lučka Debevec, Tina Jerič, Viljem Kovač, Marko Bitenc, Mihael Sok, 2009, izvirni znanstveni članek Povzetek: Background. The aim of the study was to establish eventual progress in routine management of lung cancer patients over a ten-year period at University Clinic for Respiratory and Allergic Diseases Golnik, Slovenia, comparing the results of analysis of 345 patients, diagnosed in 1996 (with analysis performed in 2002), and 405 patients, diagnosed in 2006 (with analysis performed in 2008).Patients and methods. The patients of both analysed groups were of comparable age and number of patients in stage I and II, but there were relatively more females, patients with better performance status, more precise clinical staging and tumour histology in the 2006 group. The parameters used for assessing the progress of management were as follows: time period from admittance to diagnosis and to surgery; precision of staging; accordance of clinical and pathological staging in resected patients; percentage of exploratory thoracotomy; and use of new treatment modalities. The proportion of patients in selected/actual primary treatment modality and survival rate could also be used for assessing the progress. Results. Althoughunessential longer time from admittance to microscopic confirmed diagnosis increased from a mean 7.4 to 8.6 days in 2006 progress was established by the following: more precise clinical staging (stage I and II also A and B stage, TNM staging also in small-cell lung cancer patients); improved accordance with clinical and pathological staging in resected patients (46% against 58%); decreased percentage of exploratory thoracotomy (13% against 4%); increased use of multimodality therapy as primary treatment modality (radiotherapy/chemotherapy, neoadjuvant chemotherapy); newly performed radio frequency tumour ablation. The proportion in selected/actual surgery increased from 76% to 93% and median survival rate of all patients from 6.2 to 10.6 months. (Abstract truncated at 2000 characters)
Objavljeno v DiRROS: 08.03.2024; Ogledov: 681; Prenosov: 147
Celotno besedilo (80,75 KB) |
3. Preoperative concomitant chemoradiotherapy in esophageal cancerBoštjan Šeruga, Mihael Sok, Janez Eržen, Jože Jerman, Boris Jančar, Branko Zakotnik, 2006, izvirni znanstveni članek Povzetek: Background. Currently primary treatment options for esophageal cancer are surgery only or concomitant chemoradiotherapy (CRT) and the long-term survivalof patients with locally advanced disease is rare. Preoperative concomitant CRT seems to be beneficial, mostly in patients who achieve a complete pathologic response (pCR) after CRT. In this retrospective analysis the efficiency and toxicity of preoperative CRT in patients with locally advanced esophageal cancer was analysed as well as the influence of pCR on thesuraival. Patients and metkods From 1996 to 2002 41 patients with locoregionally confined esophageal cancerwere treated with cisplatin 75 mgžm2 and 5-FU 1000 mgžm2 as 4 day contonuous infusion starting on days 1. and 22. with concorrtitant radiotherapy 4500 cGy, 200-300 cGyžday. Esophagectomy followed 4-5 weeks after radiotherapy. After the surgery patients were followed-up regularly at 3-6 months intervals. Results. The pCR was achieved in 26.8% of patients. The overall median survival time was 18 months for all patients, 21.2 months for patients who achieved pCR and 16 months in those with residual disease (p= 0,79). Postoperative mortality rate was 22%. The median dose intensity for cisplatin was 92% and for 5-FU 71.5 of the planned dose. Disease recurred most often locoregionally (31.7%) and the overall recurrence rate was 43.9. Conclusion. Modern radiation techniques and the adequate dose intensity could further improve the locoregional control. The selection of patients without comorbid conditions and without already present distant metastases is essential for this combined treatment approach.
Objavljeno v DiRROS: 15.02.2024; Ogledov: 676; Prenosov: 159
Celotno besedilo (123,83 KB) |
4. Surgical treatment of malignant pleural mesotheliomaJanez Eržen, Stanko Vidmar, Mihael Sok, Andrej Debeljak, Peter Kecelj, Viljem Kovač, Marjeta Stanovnik, Tomaž Rott, Izidor Kern, 2005, izvirni znanstveni članek Povzetek: Background. The aim of the study was to identify perioperative morbidity and mortality, the category and mode of adjuvant treatment, local recurrence and survival in patients treated by extrapleural pneumonectony (EPP) for malignantpleural mesothelioma (NLPM). Methods. From 2000 to 2003, 18 patients with MPM were referred to the Department of Thoracic Surgery in Ljubljana, and17 of them were operated on. Two patients underwent explorative thoracotomy, and 15 patients were evaluated. Five female and nine male patients (aged 52-68 years) were treated by EPP and one male patient by pleurectomy. Eight patients received both adjuvant chemotherapy (ChT) and radiotherapy (RT), with cisplatin 100 mg/m2 + mitomycin C 6-10 mg/m2 gemcitabine 1000 mg/m2 and external beam radiation with 24 Gy - 58 Gy respectively, three patients received no adjuvant therapy, three patients weretreated by adjuvant ChT, two of them were given cisplatin 100 mg/m2 + mitomycin C 6-10 mg/m2, and one patient cisplatin 100 mg/m2 on the first day and gemcitabine 250 mg/rn2 in prolonged 6 hours infusion on the first and on the eighth day. One patient was treated only by adjuvant RT. Results. There were no perioperative deaths and the postoperative morbidity was 42%. Of the 15 evaluable patients, and in the median follow up of 40 months (28-64), we noticed nine (60.0%) recurrences, seven local and two abdominal. Eight (53.3%)patients died, all because of the local progress of disease. (Abstract truncated at 2000 characters)
Objavljeno v DiRROS: 14.02.2024; Ogledov: 719; Prenosov: 162
Celotno besedilo (82,10 KB) |
5. Plasma membrane fluidity alterations in cancerous tissuesMarjeta Šentjurc, Mihael Sok, Gregor Serša, 1998, izvirni znanstveni članek Povzetek: Plasma membrane is a heterogeneous structure with several coexisting domains having different fluidity characteristics. It plays an important role in the control of cell growth, differentiation and transformation. Fluidity of the whole plasma membrane reflects the ordering and dynamics of phospholipid acyl chains in specific membrane domains, as well as the fraction of each domain inthe membrane. Changes in the membrane fluidity affect processes on the membrane such as transport, enzyme activities and expression of the redeptors.In this paper we present results of our recent electron paramagneticresonance (EPR) studies of plasma membrane fluidity characteristics, which take into account heterogeneous nature of the plasma membrane, By the computer simulation of the EPR spectra line-shapes, the number of coexisting domains in the plasma membrane, their relative portion inthe membrane as well as the ordering and dynamics of each domain be determined. Therefore, we could distinguish the contribution of the relative portion of each domain from the contribution of fulidity alterations in the domain to the entire fluidity changes in the membrane. Two examples will be discussed: membrane fluidity characteristics of excised lung tumor tissues andinfluence of microtubule depolymerizing agent vinblastine on membrane fluidity of vinblastine sensitive and resistant HeLa cells.
Objavljeno v DiRROS: 19.01.2024; Ogledov: 747; Prenosov: 179
Celotno besedilo (1,91 MB) |
6. On mechanisms of cell plasma membrane vesiculationVeronika Kralj-Iglič, Urška Batista, Henry Hägerstrand, Aleš Iglič, Janja Majhenc, Mihael Sok, 1998, izvirni znanstveni članek Ključne besede: budding, membrane bilayer, vesiculation
Objavljeno v DiRROS: 19.01.2024; Ogledov: 615; Prenosov: 194
Celotno besedilo (1,68 MB) |
7. |
8. Rak požiralnika : kaj morate vedeti o bolezni?Franc Anderluh, Irena Oblak, Vaneja Velenik, Janja Ocvirk, Zvezdana Hlebanja, Martina Reberšek, Mihael Sok, 2008, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: dejavniki tveganja, simptomi, diagnostika
Objavljeno v DiRROS: 10.08.2020; Ogledov: 2370; Prenosov: 756
Celotno besedilo (1,34 MB) |
9. Smernice za zdravljenje bolnikov z rakom požiralnika in ezofagogastričnega stika (EGS)2016, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: rak požiralnika, rak ezofagogastritičnega stika, smernice, zdravljenje
Objavljeno v DiRROS: 27.05.2020; Ogledov: 2585; Prenosov: 800
Celotno besedilo (495,34 KB) |
10. Smernice za diagnostiko in zdravljenje bolnikov z rakom pljučJože Antonič, Tanja Bavčar-Vodovnik, Olga Cerar, Rok Cesar, Anton Crnjac, Andrej Debeljak, Majda Drnovšek, Janez Eržen, Matjaž Fležar, Jože Jerman, Maja Jerše, Peter Kecelj, Izidor Kern, Igor Kocijančič, Viljem Kovač, Nada Rotovnik-Kozjek, Karmen Kramer Vrščaj, Slavica Lahajnar, Ilonka Osrajnik, Tomaž Rott, Andreja A. Schwarzbartl-Pevec, Anja Simonič, Uroš Smrdel, Mihael Sok, Andreja Cirila Škufca Smrdel, Saša Štern, Marjeta Terčelj-Zorman, Nadja Triller, Matjaž Turel, Tomaž Varga, Bojan Veingerl, Barbara Vidergar-Kralj, Stanko Vidmar, Martina Vrankar, Vesna Zadnik, Branko Zakotnik, Jurij Zalar, Anton Zorko, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Objavljeno v DiRROS: 27.05.2020; Ogledov: 2837; Prenosov: 805
Celotno besedilo (647,73 KB) |
